Seer (SEER) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Apr, 2026Executive summary
Radoff-JEC Group issued a non-binding, unsolicited proposal to acquire all outstanding shares of Class A common stock, which the board is reviewing with independent advisors.
The board will announce its decision regarding the acquisition proposal in due course and has emphasized business continuity.
Forward-looking statements highlight potential risks and uncertainties, with reference to ongoing SEC filings for further details.
Voting matters and shareholder proposals
Radoff-JEC Group nominated three director candidates for election at the 2026 Annual Meeting.
The Corporate Governance and Nominating Committee will evaluate these nominees per company bylaws, with a formal recommendation to be included in the proxy statement.
Board of directors and corporate governance
Current board members include Omid Farokhzad, Meeta Gulyani, Robert Langer, Terrance McGuire, Deep Nishar, Isaac Ro, and Nicolas Roelofs.
The board and management team are actively managing the acquisition proposal and related nominations.
Latest events from Seer
- Received unsolicited acquisition proposal and director nominations; board review underway.SEER
Proxy filing14 Apr 2026 - Strong growth, innovation, and new detector tech set the stage for future expansion.SEER
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - 2025 revenue rose 17% to $16.6M, with improved margins and a 67% increase in installed base.SEER
Q4 202526 Feb 2026 - Q2 revenue fell 23% to $3.1M; guidance cut, but cash remains strong and pipeline is growing.SEER
Q2 20242 Feb 2026 - High-impact publications and scientific validation drive optimism for growth in 2025.SEER
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Proteograph's robust, scalable platform accelerates unbiased biomarker discovery and scientific adoption.SEER
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue fell 3% to $4.0M; net loss was $21.3M; new Thermo Fisher partnership announced.SEER
Q3 202416 Jan 2026 - Proteograph's scale and partnerships are accelerating unbiased proteomics adoption and discovery.SEER
Guggenheim Securities Inaugural Healthcare Innovation Conference15 Jan 2026 - Accelerating global adoption and innovation in deep proteomics drive strong 2025 outlook.SEER
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026